ITBO910476A0 - -formulazioni farmeceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali. - Google Patents

-formulazioni farmeceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali.

Info

Publication number
ITBO910476A0
ITBO910476A0 IT91BO476A ITBO910476A ITBO910476A0 IT BO910476 A0 ITBO910476 A0 IT BO910476A0 IT 91BO476 A IT91BO476 A IT 91BO476A IT BO910476 A ITBO910476 A IT BO910476A IT BO910476 A0 ITBO910476 A0 IT BO910476A0
Authority
IT
Italy
Prior art keywords
vaginal
treatment
pharmaceutical formulations
formulations containing
infections
Prior art date
Application number
IT91BO476A
Other languages
English (en)
Inventor
Egidio Marchi
Leone Gabriele Rotini
Subhash Desai
Massimo Grilli
Original Assignee
Alfa Wassermann Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfa Wassermann Spa filed Critical Alfa Wassermann Spa
Publication of ITBO910476A0 publication Critical patent/ITBO910476A0/it
Priority to ITBO910476A priority Critical patent/IT1253711B/it
Priority to US07/899,421 priority patent/US5314904A/en
Priority to TW081105403A priority patent/TW217385B/zh
Priority to CA002073601A priority patent/CA2073601C/en
Priority to KR1019920012471A priority patent/KR0149519B1/ko
Priority to MX9204132A priority patent/MX9204132A/es
Priority to ES92113603T priority patent/ES2081531T3/es
Priority to DK92113603.2T priority patent/DK0547294T3/da
Priority to EP92113603A priority patent/EP0547294B1/en
Priority to DE69206245T priority patent/DE69206245T2/de
Priority to AT92113603T priority patent/ATE130510T1/de
Priority to JP4266034A priority patent/JP2834951B2/ja
Publication of ITBO910476A1 publication Critical patent/ITBO910476A1/it
Priority to US08/181,259 priority patent/US6140355A/en
Application granted granted Critical
Publication of IT1253711B publication Critical patent/IT1253711B/it
Priority to GR950403212T priority patent/GR3018205T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
ITBO910476A 1991-12-17 1991-12-17 Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali IT1253711B (it)

Priority Applications (14)

Application Number Priority Date Filing Date Title
ITBO910476A IT1253711B (it) 1991-12-17 1991-12-17 Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali
US07/899,421 US5314904A (en) 1991-12-17 1992-06-16 Pharmaceutical compositions containing rifaximin for treatment of vaginal infections
TW081105403A TW217385B (it) 1991-12-17 1992-07-08
CA002073601A CA2073601C (en) 1991-12-17 1992-07-10 Pharmaceutical compositions containing rifaximin for treatment of vaginal infections
KR1019920012471A KR0149519B1 (ko) 1991-12-17 1992-07-14 질감염 치료용 질의약 조성물과 그 제조 방법
MX9204132A MX9204132A (es) 1991-12-17 1992-07-15 Composiciones farmaceuticas que contienen rifaximin y procedimiento para su preparacion.
ES92113603T ES2081531T3 (es) 1991-12-17 1992-08-10 Composiciones farmaceuticas que contienen rifaximina para el tratamiento de infecciones vaginales.
DK92113603.2T DK0547294T3 (da) 1991-12-17 1992-08-10 Farmaceutiske præparater indeholdende rifaximin til behandling af vaginalinfektioner
EP92113603A EP0547294B1 (en) 1991-12-17 1992-08-10 Pharmaceutical compositions containing rifaximin for treatment of vaginal infections
DE69206245T DE69206245T2 (de) 1991-12-17 1992-08-10 Rifaximin enthaltendes Arzneimittel zur Behandlung von Vaginalinfektionen.
AT92113603T ATE130510T1 (de) 1991-12-17 1992-08-10 Rifaximin enthaltendes arzneimittel zur behandlung von vaginalinfektionen.
JP4266034A JP2834951B2 (ja) 1991-12-17 1992-10-05 細菌性腟症用予防および治療剤
US08/181,259 US6140355A (en) 1991-12-17 1994-01-13 Pharmaceutical compositions containing rifaximin for treatment of vaginal infections
GR950403212T GR3018205T3 (en) 1991-12-17 1995-11-23 Pharmaceutical compositions containing rifaximin for treatment of vaginal infections.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITBO910476A IT1253711B (it) 1991-12-17 1991-12-17 Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali

Publications (3)

Publication Number Publication Date
ITBO910476A0 true ITBO910476A0 (it) 1991-12-17
ITBO910476A1 ITBO910476A1 (it) 1993-06-17
IT1253711B IT1253711B (it) 1995-08-23

Family

ID=11337881

Family Applications (1)

Application Number Title Priority Date Filing Date
ITBO910476A IT1253711B (it) 1991-12-17 1991-12-17 Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali

Country Status (13)

Country Link
US (2) US5314904A (it)
EP (1) EP0547294B1 (it)
JP (1) JP2834951B2 (it)
KR (1) KR0149519B1 (it)
AT (1) ATE130510T1 (it)
CA (1) CA2073601C (it)
DE (1) DE69206245T2 (it)
DK (1) DK0547294T3 (it)
ES (1) ES2081531T3 (it)
GR (1) GR3018205T3 (it)
IT (1) IT1253711B (it)
MX (1) MX9204132A (it)
TW (1) TW217385B (it)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US20030091629A1 (en) * 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US6462030B1 (en) * 1999-07-19 2002-10-08 New York Blood Center, Inc. Method for inactivating bacteria associated with bacterial vaginosis using cellulose acetate phthalate and/or hydroxypropyl methycellulose phthalate
US6251136B1 (en) * 1999-12-08 2001-06-26 Advanced Cardiovascular Systems, Inc. Method of layering a three-coated stent using pharmacological and polymeric agents
ES2357474T3 (es) 2000-03-07 2011-04-26 Rush-Presbyterian-St.Luke's Medical Center Composiciones y su uso para atrapar e inactivar microbios patógenos y espermatoziodes.
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US6537538B2 (en) 2000-12-18 2003-03-25 Rush-Presbyterian-St. Luke's Medical Center Method for the prevention, inhibition, or treatment of vaginitis and/or bacterial vaginosis using polystyrene sulfonate
KR100392363B1 (ko) * 2000-12-26 2003-07-22 한국전자통신연구원 형광체 및 그 제조방법
CN1259049C (zh) * 2001-07-06 2006-06-14 苏坎波公司 包含白介素－2抑制剂和抗菌剂的局部给药组合物
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
EP1556009B2 (en) 2002-10-25 2021-07-21 Foamix Pharmaceuticals Ltd. Cosmetic and pharmaceutical foam
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
ES2385477T3 (es) 2002-11-05 2012-07-25 Fadim S.R.L. Liberación continua y controlada de rifaximina
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
US9241997B2 (en) * 2003-06-13 2016-01-26 Idh Holding Aps Treatment of symptoms associated with bacterial vaginosis
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
BRPI0414500A (pt) * 2003-09-19 2006-11-07 Drugtech Corp formulação farmacêutica composição para tratar uma infecção vaginal, e, métodos para tratar uma infecção vaginal, para estabilizar uma formulação de clindamicina, para tratar ou prevenir uma recorrência de uma infecção vaginal em uma paciente e para tratar condições vaginais
US20060140990A1 (en) * 2003-09-19 2006-06-29 Drugtech Corporation Composition for topical treatment of mixed vaginal infections
EP1708686B1 (en) * 2003-12-31 2011-02-16 Cima Labs Inc. Generally linear effervescent oral fentanyl dosage form and methods of administering
WO2005065317A2 (en) * 2003-12-31 2005-07-21 Cima Labs Inc. Effervescent oral fentanyl dosage form
AU2004311879B2 (en) * 2003-12-31 2010-08-05 Cima Labs Inc. Effervescent oral opiate dosage form
WO2005085287A1 (en) * 2004-03-03 2005-09-15 En-N-Tech, Inc. Treatments for contaminant reduction in lactoferrin preparations and lactoferrin-containing compositions
US20060210492A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Use of rifaximin for treatment and prevention of periodontal conditions
US20060210483A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
US8003118B2 (en) * 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
CN101170993A (zh) * 2005-05-09 2008-04-30 药物技术公司 修饰释放的药物组合物
CA2610662A1 (en) * 2005-05-09 2007-05-18 Foamix Ltd. Foamable vehicle and pharmaceutical compositions thereof
EA200870153A1 (ru) * 2006-01-05 2008-12-30 Драгтек Корпорейшн Композиция и способ ее использования
KR20080083190A (ko) * 2006-01-05 2008-09-16 드러그테크 코포레이션 외음질 표면에 생체접착을 위한 약물 전달 시스템
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
US20080159987A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Restless Legs Syndrome
WO2008106646A2 (en) * 2007-03-01 2008-09-04 Introgen Therapeutics, Inc Methods and formulations for topical gene therapy
AU2016203925B2 (en) * 2007-07-06 2016-10-20 Lupin Limited Pharmaceutical compositions of rifaximin
AU2008273699A1 (en) * 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
DK2011486T3 (da) * 2007-07-06 2012-09-03 Lupin Ltd Farmaceutiske sammensætninger af rifaximin
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
WO2010041141A2 (en) 2008-10-07 2010-04-15 Foamix Ltd. Oil-based foamable carriers and formulations
WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
EP2242476A2 (en) 2008-01-14 2010-10-27 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US8980872B2 (en) 2008-09-26 2015-03-17 Aska Pharmaceutical Co., Ltd. Agent for preventing and/or treating functional gastrointestinal disorder
US20120087872A1 (en) 2009-04-28 2012-04-12 Foamix Ltd. Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof
WO2011013008A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US10029013B2 (en) 2009-10-02 2018-07-24 Foamix Pharmaceuticals Ltd. Surfactant-free, water-free formable composition and breakable foams and their uses
PE20121185A1 (es) * 2009-10-27 2012-09-15 Lupin Ltd Dispersion solida de rifaximina
CA2781580A1 (en) * 2009-11-23 2011-05-26 Cipla Limited Topical foam composition
KR20120099731A (ko) 2009-11-23 2012-09-11 시플라 리미티드 국소용 폼 조성물
US7888062B1 (en) 2010-02-01 2011-02-15 Microbios, Inc. Process and composition for the manufacture of a microbial-based product
US8445226B2 (en) * 2010-02-01 2013-05-21 Microbios, Inc. Process and composition for the manufacture of a microbial-based product
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
WO2012076832A1 (en) 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
CN102512358B (zh) * 2011-12-16 2013-04-10 南京农业大学 家畜用利福昔明阴道栓剂及其制备方法
AU2014229467A1 (en) 2013-03-15 2015-08-06 Alfa Wassermann S.P.A. Rifaximin for use in the treating of vaginal infections.
EP2971062A2 (en) 2013-03-15 2016-01-20 ALFA WASSERMANN S.p.A. Method for diagnosing vaginal infections
JP6576953B2 (ja) 2014-05-12 2019-09-18 アルファシグマ ソシエタ ペル アチオニ リファキシミンの新規溶媒和物結晶形、生成物、組成物及びそれらの使用
CA2959414C (en) 2014-09-05 2023-03-14 Symbiomix Therapeutics, Llc Secnidazole for use in the treatment of bacterial vaginosis
PL3261683T3 (pl) 2015-02-26 2019-08-30 Fundació Institut D'investigació En Ciències De La Salut Germans Trias I Pujol Kompozycja do stosowania miejscowego do leczenia uszkodzeń błony śluzowej
MX2020012139A (es) 2016-09-08 2021-01-29 Vyne Pharmaceuticals Inc Composiciones y metodos para tratar rosacea y acne.
US20190008784A1 (en) * 2017-07-07 2019-01-10 Symbiomix Therapeutics, Llc Novel secnidazole soft gelatin capsule formulations and uses thereof
WO2019073321A1 (en) * 2017-10-10 2019-04-18 Zenvision Pharma Llp EFFERVESCENT COMPOSITIONS COMPRISING RIFAXIMINE
WO2022090490A1 (en) * 2020-10-29 2022-05-05 Bausch Health Ireland Limited Rifaximin liquid formulations for use in the treatment of sickle cell disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD204925A5 (de) * 1980-09-25 1983-12-14 Ciba Geigy Ag Verfahren zur herstellung eines 4-aminoimidazolo (4,5-c)rifamycins sv oder s
ZA816635B (en) * 1980-09-25 1982-09-29 Ciba Geigy Novel 2-aminoimidazoles
IT1190445B (it) * 1985-11-08 1988-02-16 Fatro Spa Composizioni veterinarie a base di agenti antimicrobici e loro impiego
DE3815221C2 (de) * 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
DE69011557T2 (de) * 1989-03-31 1995-03-23 Lepetit Spa Verwendung von Purpuromycin zur Behandlung von Vaginalinfektionen.
GB8908250D0 (en) * 1989-04-12 1989-05-24 Fisons Plc Formulations
GB9001019D0 (en) * 1990-01-17 1990-03-14 Euro Celtique Sa Pharmaceutical aerosol

Also Published As

Publication number Publication date
ES2081531T3 (es) 1996-03-16
US6140355A (en) 2000-10-31
TW217385B (it) 1993-12-11
CA2073601A1 (en) 1993-06-18
DE69206245D1 (de) 1996-01-04
DK0547294T3 (da) 1995-12-18
JP2834951B2 (ja) 1998-12-14
JPH05255085A (ja) 1993-10-05
DE69206245T2 (de) 1996-05-02
GR3018205T3 (en) 1996-02-29
KR0149519B1 (ko) 1998-10-15
US5314904A (en) 1994-05-24
KR930012015A (ko) 1993-07-20
MX9204132A (es) 1993-08-01
IT1253711B (it) 1995-08-23
ATE130510T1 (de) 1995-12-15
CA2073601C (en) 1996-07-09
EP0547294A1 (en) 1993-06-23
ITBO910476A1 (it) 1993-06-17
EP0547294B1 (en) 1995-11-22

Similar Documents

Publication Publication Date Title
ITBO910476A0 (it) -formulazioni farmeceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali.
ITMI920528A0 (it) 14-beta idrossi-10-de acetil-baccatina iii, suoi derivati, loro preparazione ed impiego terapeutico
MX9202839A (es) 4-aminoquinolinas y composiciones farmaceuticas de las mismas.
MX9204301A (es) Acilmercaptoalcanoildipeptidos, metodos de preparacion y su uso terapeutico.
IT1271462B (it) Antagonisti delle tachichinine,procedimento per la loro preparazione e loro impiego in formulazioni farmaceutiche.
CA2105487A1 (en) Antiviral nucleoside combination
FI934914A (fi) Farmaceutiska formuleringar
ITMI911096A0 (it) Composti di sintesi atti all'impiego nella terapia delle infezioni da rhinovirus
ITMI922779A1 (it) Antagonisti delle tachichinine, procedimento per la loro preparazione e loro impiego in formulazioni farmaceutiche
ITMI912509A1 (it) Uso della nimesulide nel trattamento della cataratta
ITMI911470A1 (it) N-(5-tioxo-l-prolil)-l-cisteina e suoi derivati, loro preparazione ed impiego terapeutico
IT1291340B1 (it) Formulazioni farmaceutiche contenenti colostro e uso del colostro per il trattamento di affezioni del cavo orale
MX9200532A (es) Agente farmaceuticos.
ITMI912261A1 (it) Composizioni farmaceutiche contenenti clozapina, loro preparazione e loro impiego
IT8319600A0 (it) Composizioni farmaceutiche e loro uso nel trattamento del glaucoma.
IT9019565A0 (it) Agenti addensanti,loro preparazione ed uso
ITFI920089A0 (it) Composti triciclici antagonisti delle tachichinine, loro preparazione e loro uso in composizioni farmaceutiche.
BR9106372A (pt) Derivados 1,5-benzotiazepinona,suas preparacoes e uso farmaceutico
IT9048026A0 (it) Preparato farmaceutico e/o cosmetico.
FI935915A (fi) 2-tienyyli-imidatso(2,1-b)bentsotiatsol-3-etikkahappojohdannaiset, niiden valmistus ja terapeuttinen käyttö
EP0449427A3 (en) Use of an antihistamine in the treatment of alcohol intoxication
EP0462621A3 (en) Use of particular compounds for manufacture of pharmaceutical formulations for treatment against various parasites, mycoplasmas, other indications and other infections
ITMI911930A1 (it) Composizioni farmaceutiche di stereoisomeri di ossiracetam e loro impiego terapeutico.
ITMI912264A1 (it) Composizioni utili nella terapia delle affezioni del sistema immunitario e delle anemie
ZA902254B (en) Use of purpuromycin for the treatment of vaginal infections and pharmaceutical dosage forms for said use

Legal Events

Date Code Title Description
0001 Granted